

**North Central London**

**Joint Formulary Committee**

|  |
| --- |
| **Medicine and Indication****Position Statement** |

|  |
| --- |
| **Key points of position statement** |

**References**

|  |  |
| --- | --- |
| Groups / Individuals who have overseen the development of this guidance: |  |
| Groups which were consulted and have given approval: |  |
| File name: |  |
| Version number: | V1 |
| Available on: | <https://www.ncl-mon.nhs.uk/> |
| Disseminated to: | All Trusts and CCGs in NCL |
| Equality impact assessment: |  |
| NCL Joint Formulary Committee Approval date: |  |
| Review date: |  |